It is my privilege to announce that PICCOLETO II RCT has just been published in JACC Int, November 2020.

For the first time, a DCB (Elutax SV/Emperor) outperformed a new-gen DES in terms of angiographic endpoint, in the native vessel disease setting.

I am including here the PDF version of the paper for your reference.

https://www.jacc.org/doi/10.1016/j.jcin.2020.08.035